Screener
Gilead Sciences GILD Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| -$10.5B-636% | $2.02B+53.7% | $2.18B+22.4% | $3.05B+144% | $1.96B+21.4% | ||
| $98M+5.4% | —— | $597M-0.2% | $90M-4.3% | $93M-5.1% | ||
| $231M+2.7% | $218M+4.3% | $230M+3.6% | $230M+6.5% | $225M+7.1% | ||
| $3.57B+332% | $2.54B+44.8% | $3.33B+11.8% | $4.11B-4.7% | $827M-37.6% | ||
| $140M+30.8% | $117M+12.5% | $205M+39.5% | $147M+4.3% | $107M-17.7% | ||
| $11.21B+53,276% | $109M-60.1% | $609M+712% | $167M-70.7% | $21M-86.2% | ||
| -$10.35B-389% | $1.77B+527% | -$1.84B-716% | -$427M+39.9% | -$2.12B-589% | ||
| $1.03B+3.5% | $1.04B+3.0% | $994M+2.2% | $1.01B+2.2% | $994M+2.3% | ||
| $355M-32.6% | $419M-42.6% | $230M-34.3% | $435M+45.0% | $527M+427% | ||
| —— | —— | $8M+14.3% | $9M-92.0% | $9M-99.5% | ||
| —— | -$4.24B-23.7% | -$1.26B— | -$1.49B-8.0% | -$1.57B+46.9% | ||
| -$4.45B-59.9% | $65M+103% | —— | —— | -$2.78B-43.0% | ||
| $3.43B+377% | $2.43B+46.8% | $3.12B+10.4% | $3.96B-5.0% | $720M-39.7% |
FAQ
- How much cash does Gilead Sciences generate?
- Gilead Sciences (GILD) generated $13.6B in operating cash flow over the trailing twelve months.
- What is Gilead Sciences's free cash flow?
- After $609.0M of capital expenditures, Gilead Sciences's free cash flow was $12.9B over the trailing twelve months, up 38.1% year over year.
- Where does Gilead Sciences's cash flow data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
